Opus Genetics, Inc. (IRD)
NASDAQ: IRD · Real-Time Price · USD
1.010
+0.020 (2.02%)
Jun 5, 2025, 10:35 AM - Market open

Company Description

Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of inherited retinal diseases (IRDs).

It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease.

The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutations; OPGx-RDH12 that is designed to restore protein expression and halt functional deterioration in patients with retinal dystrophy caused by mutations in the retinal dehydrogenase gene; OPGx-MERTK, an AAV vector for the treatment of MERTK IRD; OPGx-NMNAT1, a gene augmentation therapy designed to halt functional deterioration in pediatric patients with retinal degenerative disease caused by mutations in the nicotinamide mononucleotide adenylyltransferase 1 gene; and OPGx-CNGB1, an AAV gene therapy for retinitis pigmentosa due to mutations in the CNGB1 gene.

In addition, it develops Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as for the treatment of presbyopia and dim light or night vision disturbances; and APX3330, a small-molecule inhibitor of Ref-1 for the treatment of diabetic retinopathy.

The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Durham, North Carolina.

Opus Genetics, Inc.
Opus Genetics logo
Country United States
Founded 2018
Industry Biotechnology
Sector Healthcare
Employees 18
CEO George Magrath

Contact Details

Address:
8 Davis Drive, Suite 220
Durham, North Carolina 27709
United States
Phone 984 884 6030
Website opusgtx.com

Stock Details

Ticker Symbol IRD
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001228627
ISIN Number US67577R1023
Employer ID 11-3516358
SIC Code 2834

Key Executives

Name Position
George Magrath M.B.A., M.D., M.S. Chief Executive Officer and Director
Dr. Benjamin R. Yerxa Ph.D. President and Director
Nirav Suresh Jhaveri C.F.A. Chief Financial Officer
Dr. Ashwath Jayagopal Ph.D. Chief Scientific and Development Officer
Joseph K. Schachle MBA Chief Operating Officer
Bernhard Hoffmann M.B.A. Senior Vice President of Corporate Development and Secretary
Amy Zaremba Rabourn C.P.A., MAcc Senior Vice President of Finance
Bindu Manne Head of Market Development and Commercialization
Erik Sims Director and Corporate Controller

Latest SEC Filings

Date Type Title
May 15, 2025 SCHEDULE 13G Filing
May 15, 2025 10-Q Quarterly Report
May 15, 2025 8-K Current Report
May 6, 2025 SCHEDULE 13D/A Filing
May 1, 2025 8-K Current Report
Apr 14, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 11, 2025 PX14A6G Notice of exempt solicitation submitted by non-management
Apr 11, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 10, 2025 EFFECT Notice of Effectiveness
Apr 10, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material